swog s1801: benefits of neoadjuvant immunotherapy for patients with resectable melanoma
Published 1 year ago • 183 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
0:27
swog s1801: escalation vs. deescalation of immunotherapy for melanoma
-
0:35
potential advantages of neoadjuvant immunotherapy for melanoma
-
0:37
swog s1801: pathologic response in neoadjuvant-adjuvant vs. adjuvant pembro for resectable melanoma
-
3:09
advances in utilizing neoadjuvant immunotherapy in melanoma
-
4:58
expert report on neoadjuvant immune checkpoint inhibitors for melanoma
-
1:20
neopele: neoadjuvant pembrolizumab and lenvatinib in resectable stage iii melanoma
-
1:39
opacin and opacin-neo: neoadjuvant immunotherapy for advanced melanoma
-
1:27
emerging trials in melanoma: swog s1801, opacin-neo and prado
-
1:22
the personalization of neoadjuvant immunotherapy in stage iii melanoma
-
1:54
neoadjuvant immunotherapy improves outlook in high-risk melanoma
-
0:40
gamma signature guidance in optimizing neoadjuvant immunotherapy for resectable melanoma
-
3:44
neoadjuvant approaches in melanoma
-
10:42
what is new in melanoma?
-
2:10
neoadjuvant therapy for melanoma
-
1:14
adjuvant and neoadjuvant clinical trials for melanoma
-
1:48
adjuvant and neoadjuvant chemo-io for uk patients with nsclc
-
2:43
clinical & tumor characteristics of patients with recurrent melanoma upon immunotherapy
-
0:36
treating desmoplastic melanoma with single agent immunotherapy
-
2:14
the use of neoadjuvant studies to prevent melanoma from recurring